Erdafitinib-associated Subretinal Fluid in a 75-Year-Old Man With Vitreomacular Traction

Fibroblast growth factor receptor (FGFR) inhibitors are increasingly used in cancer therapy but cause ocular side effects, including subretinal fluid (SRF). Baseline vitreomacular traction (VMT) may predispose patients to drug-induced SRF. A 75-year-old man with bladder cancer and VMT developed SRF after initiating erdafitinib therapy. Baseline and follow-up findings were analyzed, including ophthalmic examinations, optical coherence tomography (OCT), and fluorescein angiography (FA). One month after starting erdafitinib, the patient's vision decreased, and OCT revealed new bilateral SRF. Erdafitinib was discontinued, leading to gradual SRF resolution and visual acuity improvement. Repeated OCT demonstrated complete SRF resolution and stable VMT at the final follow-up visit. Erdafitinib can induce SRF, particularly in patients with predisposing retinal conditions such as VMT. Awareness of these risks and early intervention can prevent vision loss. Further research is needed to explore underlying mechanisms and preventive strategies.